Comparative Pharmacology
Head-to-head clinical analysis: NIMBEX versus PANCURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIMBEX versus PANCURONIUM BROMIDE.
NIMBEX vs PANCURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and inducing muscle relaxation.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 1-2 mcg/kg/min (initial) adjusted to effect.
0.04-0.1 mg/kg IV initial bolus, then 0.01-0.02 mg/kg IV every 20-40 min as needed for neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life approximately 20-30 minutes in healthy adults; prolonged in hepatic or renal impairment.
Terminal elimination half-life: 100-120 minutes in adults with normal renal function; prolonged to 240-480 minutes in renal failure.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal excretion accounts for <20%.
Renal: 50-70% unchanged; biliary/fecal: 5-10% as metabolites; minor hepatic metabolism.
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent